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Abstract
The Affymetrix Drug Metabolism Enzymes and Transporters (DMET) microarray is the first assay to offer a large
representation of SNPs conferring genetic diversity across known pharmacokinetic markers. As a convenient and painless
alternative to blood, saliva samples have been reported to work well for genotyping on the high density SNP arrays, but no
reports to date have examined this application for saliva-derived DNA on the DMET platform. Genomic DNA extractions
from saliva samples produced an ample quantity of genomic DNA for DMET arrays, however when human amplifiable DNA
was measured, it was determined that a large percentage of this DNA was from bacteria or fungi. A mean of 37.3% human
amplifiable DNA was determined for saliva-derived DNAs, which results in a significant decrease in the genotyping call rate
(88.8%) when compared with blood-derived DNAs (99.1%). More interestingly, the percentage of human amplifiable DNA
correlated with a higher genotyping call rate, and almost all samples with more than 31.3% human DNA produced a
genotyping call rate of at least 96%. SNP genotyping results for saliva derived DNA (n=39) illustrated a 98.7% concordance
when compared with blood DNA. In conclusion, when compared with blood DNA and tested on the DMET array, saliva-
derived DNA provided adequate genotyping quality with a significant lower number of SNP calls. Saliva-derived DNA does
perform very well if it contains greater than 31.3% human amplifiable DNA.
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Introduction
Genetic variation has been conclusively recognized as a critical
contributor of individual therapeutic efficacy and/or side effects
for any given drug. The Affymetrix Drug Metabolism Enzymes
and Transporters (DMET) microarray is the first assay enabling
the simultaneous genotyping of a large number of known markers
(1,936 markers in 225 genes) in drug Absorption, Distribution,
Metabolism & Excretion (ADME) [1–3]. The DMET array
platform has been recently used by several research groups who
have successfully identified new drug associated biomarkers [4,5].
Blood samples have proven to be a gold standard source of
genomic DNA for biomarker genotyping. However, the need to
have a health professional draw the blood as well as the invasive
character of this method significantly reduces participation rates
[6,7], and some study subjects such as psychiatric patients may be
reluctant to provide blood samples [8]. The alternative is saliva-
derived genomic DNA. The collection process is user-friendly,
painless, and cost-effective. It is made more attractive by the
availability of commercially available kits such as the Oragen-
e?DNA kit [9]. There is concern, however, of point source
microbial contamination inherent in the human saliva and how it
may interfere with array genotyping call rates [10,11] even though
the human DNA could be specifically quantified by assaying for
the human RNase P gene [12,13].
Saliva has been reported to be a reliable source for DNA
genotyping on the Affymetrix SNP 6.0 microarray platform
(Scheet et al, unpublished data) and Illumina Hap370 microarray
[14], but produces much lower genotyping call rates in Affymetrix
Mapping 500 K Array [15] and even for some individual SNP
assays [16]. The genotyping performance of saliva-derived DNA
appears to be associated with the microarray type, presumably
because of the different chemistries required to obtain the
genotypes. To date, there are no such reports demonstrating the
effect of DNA derived from human saliva on the genotyping
performance for the DMET array, and also no comparisons have
been made between blood and saliva derived DNA samples on this
platform.
This study was designed to compare genotyping performance
between blood and saliva-derived DNA on the DMET array.
More importantly, the study also evaluated possible ways to
improve the saliva-derived DNA genotyping call rate.
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The quantity and quality of genomic DNA extracted from
both saliva and blood was adequate for the DMET array
We first compared the quantity and purity of isolated genomic
DNA from both the blood and saliva samples. As shown in
Table 1, the purity of genomic DNA extracted from the saliva
samples is not significantly different than that from the blood
samples. However, the DNA yield from saliva samples is
significantly lower when compared to the blood samples.
Saliva-derived DNA contains significantly less human
amplifiable DNA, and produces a significantly lower
DMET genotyping call rate when compared with blood-
derived DNA
The amplifiable human DNA from both blood and saliva-
derived DNAs was determined using the Taqman RNase P assay.
As shown in Table 2, the mean amplifiable human DNA
percentage in saliva samples is significantly lower than that of
the blood samples (37.3% vs. 87.57%). More interestingly, the
genotyping call rate for the saliva-derived DNA is also significantly
lower than blood-derived DNAs (88.82% vs. 99.1%), which is
drastically lower than the desired genotyping call rate of 98%
suggested by the manufacturer. The reduction in call rate
correlates to an average of 1918/1936 markers called in the
blood-derived samples compared to 1719/1936 SNPs called with
the saliva-derived DNAs.
The percentage of human amplifiable DNA in saliva
samples is associated with the genotyping call rate
We evaluated the correlation of amplifiable human DNA
percentage in saliva samples and their genotyping call rates on the
DMET array. The results demonstrate that the genotyping call
rates were enhanced as amplifiable human DNA percentage was
increased (Figure 1). As a result, there is an association between the
amplifiable human DNA and the genotyping call rate. Also, we
found that most saliva samples (90%) containing =31.3%
amplifiable human DNA had a genotyping call rate .96%.
Increasing the concentration of saliva-derived DNA did
not result in a significant enhancement of the
genotyping call rate
Since a number of saliva-derived DNA samples demonstrated
lower genotyping call rates, and this appeared to be associated
with a lower amplifiable human DNA percentage, we hypothe-
sized that increasing the saliva DNA concentration would increase
the genotyping call rate by indirectly increasing the amount of
human DNA. Therefore, we chose six samples and tested their
performance on the DMET array after increasing the genomic
DNA concentration (Table 3). The genotyping call rates did not
increase or decrease when the human amplifiable DNA was
changed. As a result, there is no significant difference of
genotyping call rate between those samples with an increased
concentration (average is 84.0765.6%) when compared with the
samples at their original concentration (84.8363.61%)
(P=0.9041).
Taqman SNP assay results confirm the genotyping
quality of the DMET array
In order to evaluate the genotyping quality of markers on the
DMET array, we randomly selected five SNPs included on the
DMET marker panel, and subsequently genotyped the blood-
derived DNA samples using Taqman SNP assays. When we
compared the concordance of the genotyping results between the
DMET array and the Taqman SNP assays, there was only one
discordant genotype across all five SNPs and forty-five samples.
The DMET array produced a 99.5% concordance when
compared to a second platform (Allelic Discrimination Assay).
The DMET genotyping concordance between saliva and
blood-derived DNAs for all markers called on the DMET
array is high
39 individuals provided both saliva and blood samples, we
evaluated the genotyping concordance between the saliva and
blood-derived genotype results. The data illustrated a 98.7%
concordance across both tissues.
Discussion
Peripheral blood samples have been the dominant DNA source
for genotyping using individual SNP assays and next generation
high density SNP microarrays [14,16]. However, the requirement
of a trained staff and the painful collection process significantly
decreases the participation rate of patients [6,7], especially for
those with psychiatric diseases [8]. As a convenient, painless, and
cost-effective alternative; saliva samples have been proven to be a
good substitute to blood-derived DNAs for individual SNP assays
[17] and for various platforms utilizing microarrays [14,18].
However, the existence of exogenous point source microbial DNA
in saliva-derived genomic DNA samples can significantly decrease
the performance of the sample when genotyped on various array
platforms [15,16]. As a powerful research tool for pharmacoge-
nomic studies, the DMET microarray provides the first high
throughput platform to investigate typical pharmacokinetic
markers at one time and the resulting allele translations greatly
facilitate the use of these results in clinical applications [19,20]. To
our knowledge, this is the first time saliva-derived DNAs have been
utilized for genotyping on the DMET array platform. We
compared the genotyping performance of saliva-derived DNA
against blood-derived DNA. In addition, we also have suggested a
method to screen saliva-derived DNA to select samples that would
perform optimally on this platform.
Table 1. Comparison of DNA purity and yield between blood
and saliva samples.
DNA Source Purity (A260/A280) Yield (mg)
Blood (n=45) 1.8560.004 253.63626.6
Saliva (n=42) 1.8560.02 21.0963.64
T-test P-value 0.709 1.32142610
211
doi:10.1371/journal.pone.0033968.t001
Table 2. Comparison of amplifiable human DNA percentage
and genotyping call rate between blood and saliva derived
DNA.
DNA Source Amplifiable human DNA (%) Genotyping call rate (%)
Blood (n=45) 87.5762.38 99.1060.08
Saliva (n=42) 37.364.2 88.8261.83
T-test P-value 1.63828610
215 1.64246610
26
doi:10.1371/journal.pone.0033968.t002
DMET Array: Saliva and Blood DNA Comparison
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yield more DNA than saliva samples, which is mainly due to the
utilization of a higher blood volume (8.5 ml) than saliva (0.5 ml)
for extraction. Nevertheless, the saliva sample produced sufficient
DNA (21 mg) in regard to the minimum amount required (1.05 mg)
for DMET assays. The saliva DNA purity is very similar to that of
blood DNA, but as spectrophotometry cannot differentiate the
microbial DNA from human DNA, we utilized the RNase P
TaqMan assay to identify amplifiable human DNA. The RNase P
gene sequence is highly species-specific. The Homo sapiens RNase
P assay only detects amplifiable human DNA instead of total
genomic DNA. A limitation of this method for quantifying human
DNA is the fact that DNA degradation and PCR reaction
inhibitors may confound the results. Consequently, the amplifiable
human DNA percentage determined for our blood samples is
87%. The saliva samples contain a significantly lower percentage
of amplifiable human DNA (37.3%) when compared with blood
samples.
Interestingly, saliva-derived DNA demonstrated a significantly
lower genotyping call rate on the DMET array when compared
with blood-derived DNA. The reasons for this difference in
genotyping call rate may be explained by the unique character of
genotyping the polymorphisms on this array. The assay involves
the use of Molecular Inversion Probes (MIPs) [17,21] which
specifically recognize the SNPs, are PCR amplified, and
hybridized to the probes on the DMET array. The existence of
contaminating DNA in saliva samples may competitively interfere
with binding of the MIPs to the target SNPs and adjacent
sequences, preventing efficient target amplification. As a result,
this could affect probe hybridization and ultimately have a
negative impact on the genotyping call rate for these samples.
Our genotyping results illustrated an association between the
percentage of amplifiable human DNA with the saliva DNA
genotyping call rate. The majority (18/20) of saliva samples
containing =31.3% of amplifiable human DNA had a genotyping
call rate greater than 96%. Two samples containing 33.7% and
42.3% of human amplifiable DNA had a genotyping call rate of
91.4% and 90.89% respectively. This is consistent with another
study indicating poor genotyping performance utilizing saliva-
derived DNA with less than 30% of human amplifiable DNA on
the Affymetrix 500 K GeneChip platform [15]. These results
provide a screening method (RNase P assay) and threshold value
(31.3%) for future research groups interested in genotyping saliva
samples on the DMET array.
One goal of any molecular genetics researcher using the DMET
array is to obtain the most SNP genotype calls for their samples. At
this time, there is not a unified accepted standard for the
genotyping call rate on the DMET platform. A manufacturer
suggested threshold of 98% represents a quantity of SNP
genotypes called from the array (1897/1936), but does not infer
the quality of genotypes called. The results from this comparison
study are not meant to propose a new threshold (96%) for the
Figure 1. Association between the percentage of human DNA in saliva and the genotyping call rate of DMET arrays.
doi:10.1371/journal.pone.0033968.g001
Table 3. DMET Genotyping call rate (%) following the increasein the concentration of saliva-derived DNA.
Sample # Amplifiable Human DNA (%) 16Conc. 1.36Conc. 1.56Conc. 1.66Conc. 26Conc. 2.76Conc. 46Conc. 86Conc. 166Conc.
1 5.2 80.58 77.94 90.01
2 11.7 58.67 75.04
3 15.4 84.21 90.89 92.91
4 20.3 93.89 84.41 93.47
5 24.4 91.46 85.19 86.95 80.06 64.73
6 25.6 95.6 91.77 89.38
doi:10.1371/journal.pone.0033968.t003
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The results from this study are to simply guide researchers
considering the use of saliva-derived genomic DNA in DMET
studies, using a threshold of human amplifiable DNA as a
percentage in the sample which provides an indication that these
will then perform adequately (1857/1936 SNPs called) on the
DMET array. As a result, the researchers can screen their samples
before proceeding onto the more expensive experiment.
In attempts to improve the genotyping call rate for saliva
samples containing ,31.3% human amplifiable DNA, we
increased the concentration of input genomic DNA for the assay.
This intervention indirectly increases the absolute amount of
human amplifiable DNA required for the assay however, this did
not significantly change the genotyping call rate (84.1% vs.
84.8%). We hypothesize that the concomitant increase in
contaminating DNA may also inherently interfere with genotyping
performance.
The results from our Taqman SNP assays confirmed the
excellent genotyping quality of the DMET array platform (99.5%
reproducibility). The concordance check of genotyping calls
between saliva and blood derived DNAs, also illustrated a very
high percentage (98.7%) of SNPs with the same genotype,
demonstrating the high quality of calls for saliva samples even in
the samples in which the human DNA percentage is low. This
suggests that the contaminating DNA in saliva does not affect the
quality of the genotyping calls, but only has an effect on the
number of markers that are ultimately genotyped.
In conclusion, genomic DNA extracted from saliva and blood
produced high quality genotyping results on the DMET platform.
However, the number of markers called using saliva-derived DNA
was significantly less than that of blood-derived DNA. We have
presented a threshold (31.3%), for the percentage of human
amplifiable DNA in the saliva genomic DNA prep, which will
produce a genotyping call rate of at least 96%. This has important
implications to other research groups wishing to utilize the DMET
platform, especially if there are significant barriers to collecting
blood for a genomic DNA source or when saliva has already been
collected many years ago and biobanked.
Materials and Methods
DNA extraction
Saliva samples (n=42) were collected from patients with mental
disorders at a South Dakota Developmental Center with
ORAgene?DNA vials (DNA GenoTek, Kanata, Ontario Canada).
Genomic DNA from 500 ml of the oragene/saliva mix was
extracted with Oragene?DNA purifier following the manufactur-
er’s protocol. The concentration of the DNA sample was
determined using the NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE USA) and the DNA
yield was calculated by multiplying by the volume. The A260/
A280 ratio was used to evaluate DNA purity.
Peripheral blood samples (n=45) were collected with PAXgen-
e
TM blood DNA tubes (Qiagen, Valencia, CA USA) prefilled with
DNA stabilizing reagents. 39 individuals provided both a blood
and saliva sample. The tube containing 8.5 ml whole blood was
stored at 4uC for less than 4 weeks and DNA was extracted with
the PAXgene
TM blood DNA kit (Qiagen, Valencia, CA USA)
following the manufacturer’s protocol. DNA purity and quantity
were checked using spectrophotometry using the methods
described above.
The study protocol was approved by the Institutional Review
Board (IRB) of Avera McKennan Hospital. The guardian,
whether self or Legally Authorized Representative (LAR), signed
the informed consent and when appropriate the subject signed
Assent. The Assent was obtained from those subjects who had the
mental capacity to agree to be in the study but did not hold their
own guardianship. The guardian, if not self, was a family member
who was assigned as the LAR or state assigned guardian.
RNase P assay
The Taqman RNase P Assay (Life Technologies, Carlsbad, CA
USA) was used to measure the amount of human amplifiable DNA
in both the saliva and blood-derived DNA samples. A standard
curve was established using the human genomic control DNA
supplied in the kit, upon which the amount of human DNA in
samples are calculated. Real-time PCR was performed following
the manufacturer’s protocol. Briefly, samples were assayed using
384-well plates. To each well, 5 ml TaqMan Universal PCR
Master Mix, 0.5 ml RNase P primer-Probe Mix, 0.5 ml water, and
4 ml template DNA (10 ng/ml) was added. The PCR reaction was
performed on the Life Technologies 7900HT Fast Real-Time
PCR System using standard reaction conditions. The human
DNA percentage was determined by dividing the amount of
human DNA (as determined by the Taqman Assay) by the total
amount of DNA added to the reaction.
DMET assay
42 saliva-derived DNA samples and 45 blood-derived DNA
samples were run on the DMET microarray using the DMET Plus
Premier pack kits according to the protocol described in the
DMET Plus Premier pack User Guide. Briefly, some markers from
regions containing pseudogenes and close homologs are first pre-
amplified using a multiplex polymerase chain reaction (mPCR)
(Qiagen, Valencia, CA USA). Genomic sequences that contain the
polymorphic markers of interest are preferentially amplified
through the use of highly selective molecular inversion probes
(MIPs). A first quality control (QC) gel is run to determine the
quality of amplified MIPs, which should be a single band
represented on a gel in the range of 100–150 base pairs. Smaller
DNA fragments were generated by adding fragmentation reagents
to improve sample hybridization with the DMET plus array, and
DNA fragment size is checked on the second QC gel, in which the
fragments length should be less than 120 base pairs with a smear
centered at approximately 50 base pairs. Fragments were labeled
using the supplied labeling reagents and then hybridized to the
DMET microarray at 49uC for 16–18 hours in the Affymetrix
hybridization oven rotating at 35 rpm. Hybridized DMET arrays
were washed and stained in the Affymetrix fluidic stations and
scanned with the Affymetrix GeneChipH Scanner 3000 7G.
Genotyping data was generated with Affymetrix GeneChipH
Command console software and analyzed with the DMET
Console software.
TaqMan SNP assays
With the aim of confirming the reproducibility of genotyping
results produced by DMET assay, we chose to perform 195 tests
by selecting five SNPs (Single Nucleotide Polymorphism) from the
DMET marker panel and test 39 samples for genotype
concordance using TaqMan SNP assays in the Life Technologies
7900HT Fast Real-Time PCR System. 195 tests would enable the
detection of a 0.5% change in concordance between the two
platforms, as Affymetrix reports a 99.5% concordance to
reference. The five SNPs (rs56107638, rs2470890, rs3892097,
rs28371725, and rs762551) were selected due to their performance
on the DMET array when performing saliva genotyping. The
genotyping call rates (35.9%, 66.7%, 69.2%, 82.1%, 89.7%
respectively) for each of the five SNPs were less than or equal to
DMET Array: Saliva and Blood DNA Comparison
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DMET array (88.8%) using 39 saliva samples. The dbSNP ID,
DMET probe ID, and assay probe context sequence for each of
the SNPs tested in this experiment are listed in Table 4. The assays
were ordered from Life Technologies and real-time PCR was
performed using 2.5 ml 2X Taqman genotyping master mix,
0.125 ml 40X primer-probe mix, 1.375 ml water and 1 ml of DNA
sample (10 ng/ ml). PCR cycling conditions consisted of a 10 min
denaturation at 95uC and 40 cycles of 95uC for 15 sec and 60uC
for 1 min. The post assay analysis was performed using the Life
Technologies SDS (version 1.3) software.
DMET Console analyses
Genotyping call rate and concordance comparisons were
analyzed using the DMET Console (version 1.2) software. Fixed
Genotype Boundaries was used as the algorithm for all genotyping
configurations. The recommended QC call rate (same value as
genotyping call rate in DMET array) threshold is greater than
98%. Genotyping results from 39 patients with both saliva and
blood-derived DNAs were evaluated for SNP concordance across
both tissues.
Statistical analysis
Two-tailed Student’s t-tests were used to evaluate the differences
between saliva and blood-derived DNA samples. Significant
difference was defined as p=0.01.
Acknowledgments
We are especially thankful for the wonderful administrators and nurses at
the South Dakota Developmental Center. We would also like to thank all
of the excellent staff at the Avera Research Institute.
Author Contributions
Conceived and designed the experiments: YH EAE KB JK TJS GED.
Performed the experiments: YH EAE KN CL PH. Analyzed the data: YH
EAE KN. Wrote the paper: YH EAE GED.
References
1. Burmester JK, Sedova M, Shapero MH, Mansfield E (2010) DMET microarray
technology for pharmacogenomics-based personalized medicine. Methods Mol
Biol 632: 99–124.
2. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF (2010) Clinical
pharmacology and pharmacogenetics in a genomics era: the DMET platform.
Pharmacogenomics 11: 89–103.
3. Deeken J (2009) The Affymetrix DMET platform and pharmacogenetics in drug
development. Curr Opin Mol Ther 11: 260–268.
4. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, et al. (2008)
CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106–4112.
5. Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, et al. (2010) A
pharmacogenetic study of docetaxel and thalidomide in patients with castration-
resistant prostate cancer using the DMET genotyping platform.
Pharmacogenomics J 10: 191–199.
6. Hansen TV, Simonsen MK, Nielsen FC, Hundrup YA (2007) Collection of
blood, saliva, and buccal cell samples in a pilot study on the Danish nurse
cohort: comparison of the response rate and quality of genomic DNA. Cancer
Epidemiol Biomarkers Prev 16: 2072–2076.
7. Dlugos DJ, Scattergood TM, Ferraro TN, Berrettinni WH, Buono RJ (2005)
Recruitment rates and fear of phlebotomy in pediatric patients in a genetic study
of epilepsy. Epilepsy Behav 6: 444–446.
8. de Leon J, Susce MT, Johnson M, Hardin M, Maw L, et al. (2009) DNA
microarray technology in the clinical environment: the AmpliChip CYP450 test
for CYP2D6 and CYP2C19 genotyping. CNS Spectr 14: 19–34.
9. Rylander-Rudqvist T, Hakansson N, Tybring G, Wolk A (2006) Quality and
quantity of saliva DNA obtained from the self-administrated oragene method–a
pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev
15: 1742–1745.
10. Polgarova K, Behuliak M, Celec P (2010) Effect of saliva processing on bacterial
DNA extraction. New Microbiol 33: 373–379.
11. Lazarevic V, Whiteson K, Hernandez D, Francois P, Schrenzel J (2010) Study of
inter- and intra-individual variations in the salivary microbiota. BMC Genomics
11: 523.
12. Basham RJ, Richardson DM, Sutcliffe CB, Haas DW (2009) Effect of HIV-1
infection on human DNA yield from saliva. HIV Clin Trials 10: 282–285.
13. Quinque D, Kittler R, Kayser M, Stoneking M, Nasidze I (2006) Evaluation of
saliva as a source of human DNA for population and association studies. Anal
Biochem 353: 272–277.
14. Bahlo M, Stankovich J, Danoy P, Hickey PF, Taylor BV, et al. (2010) Saliva-
derived DNA performs well in large-scale, high-density single-nucleotide
polymorphism microarray studies. Cancer Epidemiol Biomarkers Prev 19:
794–798.
15. Herraez DL, Stoneking M (2008) High fractions of exogenous DNA in human
buccal samples reduce the quality of large-scale genotyping. Anal Biochem 383:
329–331.
16. Philibert RA, Zadorozhnyaya O, Beach SR, Brody GH (2008) A comparison of
the genotyping results using DNA obtained from blood and saliva. Psychiatr
Genet 18: 275–281.
17. Daly TM, Dumaual CM, Miao X, Farmen MW, Njau RK, et al. (2007)
Multiplex assay for comprehensive genotyping of genes involved in drug
metabolism, excretion, and transport. Clin Chem 53: 1222–1230.
18. Rasi S, Bruscaggin A, Rinaldi A, Cresta S, Fangazio M, et al. (2011) Saliva is a
reliable and practical source of germline DNA for genome-wide studies in
chronic lymphocytic leukemia. Leuk Res 35: 1419–1422.
19. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Saveria Rotundo M, et al.
(2011) Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter
genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal
cancer patients: A DMET microarray profiling study. Cancer Biol Ther 12.
20. Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, et al. (2011) A
peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is
associated with zoledronic acid-related osteonecrosis of the jaw in multiple
myeloma patients: analysis by DMET microarray profiling. Br J Haematol 154:
529–533.
21. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, et al. (2007)
Comprehensive assessment of metabolic enzyme and transporter genes using
the Affymetrix Targeted Genotyping System. Pharmacogenomics 8: 293–305.
Table 4. SNP primer-probe sets ordered from Life Technologies.
DMET probe ID dbSNP ID Context Sequence [VIC/FAM]
AM_10807 rs2470890 AGGCGCGGCTGCGCTTCTCCATCAA[T/C]TGAAGAAGACACCACCATTCTGAGG
AM_10785 rs762551 TGCTCAAAGGGTGAGCTCTGTGGGC[C/A]CAGGACGCATGGTAGATGGAGCTTA
AM_10802 rs56107638 ACCAGTGGCAGGTCAACCATGACCC[A/G]TGAGTACATACCCCTCACGAAAAAA
AM_12274 rs3892097 AGACCGTTGGGGCGAAAGGGGCGTC[C/T]TGGGGGTGGGAGATGCGGGTAAGGG
AM_12257 rs28371725 TTCATGGGCCCCCGCCTGTACCCTT[C/T]CTCCCTCGGCCCCTGCACTGTTTCC
doi:10.1371/journal.pone.0033968.t004
DMET Array: Saliva and Blood DNA Comparison
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33968